Latest News-Wuxi Biologics Mediaroom_Page

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-cl...

2023-05-16 16:00 2500

WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability

* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10%...

2023-04-28 14:43 3524

WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global...

2023-03-28 20:11 3093

WuXi Biologics Reports Remarkable 2022 Annual Results

Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to R...

2023-03-22 20:09 3787

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

* WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell ...

2023-01-05 08:30 5054

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Cont...

2022-12-16 08:44 2809

WuXi Biologics Provides Corporate Updates

SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Co...

2022-10-27 22:13 3189

WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

- The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global ma...

2022-10-26 12:30 2736

WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities

* WuXi Biologics adds further capacity and capability for drug product fill & finish, providing g...

2022-10-24 08:30 2570

WuXi Biologics Receives "Best CDMO Award of the Year"

SHANGHAI, Oct. 13, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2022-10-14 09:00 2338

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...

2022-10-12 09:00 2698

WuXi Biologics Co., Ltd. Removed from Unverified List

WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global C...

2022-10-10 07:55 4564

WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts

WORCESTER, Mass., Sept. 29, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Co...

2022-09-29 10:41 2149

WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA

WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global ...

2022-09-20 10:48 2669

WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey

CRANBURY, N.J., Aug. 31, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leadi...

2022-08-31 20:00 2867

WuXi Biologics Reports Strong 2022 Interim Results

Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB...

2022-08-17 21:32 4168

WuXi Biologics Again Selected as Constituent of FTSE4Good Index Series

SHANGHAI, Aug. 16, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Con...

2022-08-17 10:12 3160

WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore

* This investment will establish a cutting-edge, fully integrated CRDMO center inSingapore, inclu...

2022-07-19 18:03 3243

WuXi Vaccines Received First GMP Certificate of QC Potency Lab from Ireland Health Products Regulatory Authority

- The first GMP certificate that WuXi Vaccines has received from the regulatory agency - A critica...

2022-07-12 16:00 2199

WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates

SHANGHAI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- WuXi XDC, a global leading CRDMO (Con...

2022-07-08 09:27 4841